VIP vs Thymogen
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Vasoactive Intestinal Peptide, Aviptadil
VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for COVID-19 respiratory failure and pulmonary conditions. No VIP product is FDA-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people.
Also: EW Dipeptide, Glu-Trp
Thymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | VIP | Thymogen |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | VIP works through two G-protein-coupled receptors, VPAC1 and VPAC2, which are spread across immune cells, the gut, blood vessels, and the brain. When VIP binds, the receptor raises intracellular cyclic AMP, and that signal relaxes smooth muscle (so blood vessels and airways dilate) and tamps down inflammatory signaling. On the immune side, that rise in cAMP blunts NF-kB activity and lowers pro-inflammatory cytokines like TNF-alpha, which is the basis for calling VIP an endogenous anti-inflammatory. The same pathway is why researchers looked at it for the runaway lung inflammation seen in severe COVID-19. It is a broadly active hormone, not a targeted single-tissue drug, which is part of why dosing it safely is tricky. | Thymogen is meant to mimic what thymus-derived peptides do to the immune system. In experiments it has been reported to push T-cell differentiation, improve T-cell recognition of peptide-MHC complexes, shift the balance of intracellular cyclic nucleotides, and ramp up neutrophil chemotaxis and phagocytosis. In plain terms, it is proposed to wake up parts of the immune defense, especially in states where immunity is run down. Like other Khavinson peptides, it has also been described as influencing gene expression at the level of DNA, though the immunomodulatory effects are the better-documented part of its story. The exact molecular trigger that starts these effects is not fully pinned down. |
| Common Dosing | 50-100 mcg intranasal daily 1-2x daily, intranasal | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | IV infusion, inhaled, or intranasal | Oral capsules, also available as nasal spray in some regions |
| Typical Duration | Variable by indication | 30-day courses with 2-3 month breaks |
| Best Time to Take | Morning or as directed | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Most of the real human data on VIP comes from aviptadil, the synthetic analog. A randomized controlled trial of intravenous aviptadil in critically ill COVID-19 patients with respiratory failure (about 196 patients, published in Critical Care Medicine in 2022) did not hit its primary endpoint of being alive and free of respiratory failure at 60 days, though there were exploratory signals worth following up. Larger and inhaled formulations were studied through the ACTIV-3b/TESICO program, and the overall picture is mixed rather than a clear win. Beyond the lungs, VIP and its VPAC receptors are studied in rheumatoid arthritis, pulmonary arterial hypertension, and other inflammatory conditions, but that work is largely mechanistic or early-stage. There is no good human evidence supporting the anti-aging, longevity, or general wellness claims VIP is sold for online. Bottom line: a genuinely interesting immune-modulating peptide with real trials, but the trials were in serious illness and did not establish it as an effective therapy. | The most-cited international study is Anisimov and colleagues in Biogerontology (2000), where the dipeptide was given to rats and was associated with a longer maximum lifespan and markedly lower tumor incidence, including a roughly 3.4-fold drop in blood cancers versus controls. That is an animal study, not a human trial. A large body of supporting clinical and laboratory data exists, but it is overwhelmingly Russian-language, older, and produced by groups connected to the original developers, with little independent Western replication. There are no modern randomized controlled trials by outside labs confirming the immune or anti-aging claims to current evidence standards. So the fair summary is: decades of use and a real animal signal for immune and anti-tumor effects, but the high-quality, independently verified human evidence that Western medicine would want is simply not there. |
Frequently Asked Questions: VIP vs Thymogen
What is the difference between VIP and Thymogen?
VIP is a immune peptide that vip (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. it is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for covid-19 respiratory failure and pulmonary conditions. no vip product is fda-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people. Thymogen is a immune peptide that thymogen is the brand name for l-glu-l-trp (glutamyl-tryptophan, the dipeptide ew), an immune-modulating peptide isolated from the calf thymus extract thymalin. it is the smallest active piece of that thymic complex and is studied for boosting t-cell activity and immune function. it has been used clinically in russia since 1990 but has never been evaluated or approved by any western regulator, and rigorous independent trials are lacking. The main differences lie in their mechanisms of action and clinical applications.
Which is better, VIP or Thymogen?
Neither is universally "better" - the choice depends on your specific goals. VIP is typically used for immune purposes, while Thymogen is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can VIP and Thymogen be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using VIP and Thymogen together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.